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Graft dilution and DMSO washing before cord blood (CB) administration using an automated system may
offer low incidence of adverse infusion events (AIE), ensuring reproducible cell yields. Hence, we analyzed the
incidences and signiﬁcance of immediate AIE, cellular yield, and engraftment after single CB infusion. One
hundred and ﬁfty-seven patients (median age, 20 years; range, 1 to 60) received a single CB unit for treatment
of hematologic and nonhematologic malignancies with myeloablative conditioning after graft dilution and
washing. The median total nucleated cell (TNC) doses was 3.4  107/kg (range, 2 to 26) and the median post-
thaw recovery was 84% (range, 45 to 178). The cumulative incidence of neutrophil engraftment at 50 days was
84% (95% conﬁdence interval [CI], 83 to 93). A total of 118 immediate AIE were observed in ﬁfty-two (33%)
patients. All reported AIE were transient, graded from 1 to 2 by Common Terminology Adverse Events version
4. The most frequent toxicity was cardiovascular but without any life-threatening reaction. Infused TNC,
recipient’s weight, and rate of infusion per kilogram were risk factors associated with cardiovascular AIE in
multivariate analysis (odds ratio [OR], 1.2 (95% CI, 1.1 to 1.4); P < .001; OR, .94 (95% CI, .9 to .97); P < .001; and
OR, 1.5 (95% CI, 1.2 to 1.8); P < .001; respectively). In summary, use of an automated method for graft washing
before CB administration showed low incidence of AIE without compromising cell yields and engraftment.
Infused TNC dose, recipient’s weight, and rate of infusion per kilogram were risk factors associated with
infusion reactions.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Umbilical cord blood (CB) transplantation has beenincreasingly used over the past decades as an alternative
source capable of reconstituting bone marrow after alloge-
neic transplantation [1].
CB-derived hematopoietic progenitor cells (HPC) is a stem
cell source from residual placental blood collected for he-
matopoietic stem cell transplantation. It contains leukocytes
(mainly granulocytes) with variable amounts of red blood
cells (RBC) and limited numbers of CD34þ. This graft requiresedgments on page 687.
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ty for Blood and Marrow Transplantation.an optimized method for administration, including a thawing
protocol that maximizes HPC yield and minimizes adverse
infusion events (AIE) derived from adventitious substances
used for processing, cryopreservation, and residual RBC.
Rubinstein et al. [2] originally described the preparation
of CB units for infusion using albumin-dextran dilution with
centrifugation for “washing” to remove the dimethyl sulf-
oxide (DMSO), optimizing the viability of the thawed prod-
uct. However, because of the risk of cell loss, faster and easier
methods, such as albumin-dextran dilution without centri-
fugation [3] or direct infusion, have been proposed.
The causes of AIE are still not fully determined, but the
amount of infused DMSO, post-thaw cell aggregation, RBCs
lysis, and presence of granulocytes or debris [4] have also
been associated with AIE. In an attempt to diminish these
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ing of volume reduction (with plasma and RBC depletion)
before freezing, improving the clinical safety proﬁle and
facilitating the thawing procedure to prepare CB units in
transplantation centers. However, severe life-threatening AIE
occasionally have been reported [5].
To confront the latter concerns, we proposed the use of an
automated system for CB thawing to minimize intersample
variability, control timing, and ensure control of cellular
losses [6,7]. Based on this strategy, we validated an auto-
mated CB processing system for volume reduction using the
cell separator Sepax (Biosafe, Eysins, Switzerland) device.
This automated method consists of a microprocessor-
controlled cell-processing device that works as a small
blood separator with functionally closed apheresis sets that
has been implemented in CB transplantation.
Here, we conducted a retrospective study of 157 consec-
utive patients who underwent unrelated single CB trans-
plantation using this automated method thawing strategy,
and we evaluated the safety proﬁle by assessing the occur-
rence and severity of AIE.METHODS
The study included 71 pediatric and 86 adult consecutive patients who
received unrelated single allogeneic CB transplantation in the Hospital Vall
d’Hebron (Barcelona), Hospital de Sant Pau (Barcelona), Hospital Germans
Trias i Pujol (Barcelona), and Hospital Duran i Reynals (Barcelona), con-
sisting of 4 adult and 2 pediatric transplantation programs between January
2005 and December 2013. All patients with hematological and non-
hematological malignancies were eligible for enrollment if they met the
following criteria: (1) allogeneic hematopoietic cell transplantation was
considered the best therapeutic option, (2) a suitable related donor (HLA
identical or 1 antigen mismatch) was not available, (3) there was a lack of a
suitable HLA-matched unrelated donor at a reasonable time after the start of
the search through international registries, and (4) there was a suitable
umbilical CB unit available, as described below. Patients or their guardians
gave written informed consent for their inclusion in each transplantation
protocol.Transplantation Procedure
Only patients receiving a ﬁrst allograft were considered eligible for this
study. The most commonly used protocol has been previously published [8].
All patients received post-transplantation granulocyte colonyestimulating
factor from day þ7 until neutrophil recovery.
For adult patients, precryopreservation minimum cell doses required
were total nucleated cells (TNCs) > 1.5  107/kg and CD34þ cells > .6  105/
kg. A degree of HLA matching between the umbilical CB unit and the
recipient greater or equal to 4 or 6 (considering HLA-A at antigen level and
-DRB1 at allele level) was required. For pediatric patients with malignant
diseases, precryopreservation minimum cell dose required for selection was
TNC > 3  107/kg and CD34þ > 1.5  105/kg for 4 to 6/6 degree HLA
mismatch. For children with nonmalignant diseases, precryopreservation
minimum cell dose required was TNC > 5  107/kg and CD34þ > 2  105/kg
for 5 to 6/6 degree HLA mismatch.Preparation of CB Units for Infusion Using an Automated Dilution and
Washing Protocol
The CB bags stored in liquid nitrogen were thawed by immersion in a
preheated 37C water bath. When thawed, the CB bags were weighed,
samples were taken for laboratory analysis, and the bag was then connected
to a kit designed for umbilical CB cell washing and processed using the
Sepax S-100 (Biosafe) in a closed system. A stock solution of 7.5% dextran-40
(molecular weight 40,000, Fresenius Kabi, Italy) and 5% human albumin
(Grifols, Barcelona, Spain) was prepared and connected to the kit. The Sepax
software “UCB-Washing” was used. CB units were automatically diluted 1:1
with the buffer and the product was mixed in the chamber and input bag in
5 minutes. Then, the chamber was ﬁlled with the washing solution. After a
centrifugation step, the supernatant was removed and cells were diluted to
the desired infusion volume. In our laboratory, the target volumewas 70 mL
for pediatrics and 100 mL for adults. Therefore, the aggregated dilution
factor depends on the initial CB volume and ranges from 20 to 90.Cord Blood Banks and Graft Characteristics
International and Spanish Cord Blood Banks (CBBs) provided CB units for
transplantation. Prefreezing informationwas received from the original CBB
provider. Post-thaw characteristics were determined before infusion at Banc
de Sang i Teixits Cell Therapy Service, which serves as processing laboratory
for all referring transplantation units.
The prethaw amounts of DMSO and dextran were estimated from the
cryopreserved volume, according the reported DMSO concentration
(commonly available in the CB units’ attached label). When the concentra-
tionwas not reported, the banking standard of 10% DMSO and 1% dextran (v/
v) was considered. The infused amount of DMSOwas obtained following the
formula: infused DMSO (grams) ¼ 10% of cryopreserved volume/dilution
factor. For example, for a CB unit frozen in a total of 25 mL (cryopreserved
volume) and a dilution factor of 88 (25 mL of 1:1 dilution, then 170 mL to ﬁll
the chamber and an addition of 90 mL to the 10 mL pellet for a ﬁnal infusion
of 100 mL), the amount of DMSO infused is .03 grams.
CB Unit Assessment
Counting of TNC, RBC, and platelets was performed for each sample by
using an automatic cell counter that detects and measures changes in elec-
trical resistance (impedance) when a particle in a conductive liquid passes
through the device (COULTER Ac T diff, Beckman Coulter, Inc., Miami, FL).
Quality of the unit was evaluated by cytometric assay of CD34þ cell
viability using 7-aminoactinomycin D, using a modiﬁed gating that included
all dead cells [8] and colony-forming unit (CFU) assays. CFU assays were
performed using a total of 105 cells plated in duplicate and colony growth
was evaluated by light microscopy at 14 days.
As a surrogate value of CB graft potency, we used the ability of seeded
CD34þ to develop CFU (clonogenic efﬁciency). In our opinion, this value
reﬂects very well the functional characteristic of the HPC contained in the
bag [9].
Management of AIE
All patients received premedication with i.v paracetamol and i.v anti-
histamine (dexclorpheniramine or diphenhydramine) before the infusion of
the CBU, according to each institution’s protocol. Adult patients were
monitored immediately before and after progenitor infusion. Blood pres-
sure, temperature, heart and respiratory rate, diuresis, and clinical symp-
tomswere recorded in a registration form. Additionally, in pediatric patients
hematuria or hemoglobinuria were closely monitored by Labstix strip test
(Bayer, Germany) during and before infusion.
Signs and symptoms that occurred during and up to 24 hours after
infusionwere recorded by experienced transplantation nurses or physicians.
Emergency medications, including i.v. furosemide, antihypertensive drugs,
antiemetics, hydrocortisone, or oxygen, were at the patient’s bedside for use,
if needed.
Endpoints, Deﬁnitions, and Statistical Methods
Assessment of adverse infusion events
The primary endpoint of the studywas the incidence and severity of AIE,
graded by Common Terminology Criteria for Adverse Events version 4
(CTCAE v4). A severe AIE was deﬁned as 4 and 5 (life threatening and death,
respectively) or anaphylaxis, cardiac, pulmonary, or acute renal failure,
seizure, transfer to intensive care unit, or death within 48 hours of CB
infusion. We divided the immediate AIE in 2 main groups, depending on
whether patients presented with cardiovascular or noncardiovascular
events. CB units were infused in a single reduced-volume bag without
requiring additional hydration before infusion.
Assessment of donor engraftment
Myeloid engraftmentwas deﬁned as the ﬁrst of 3 consecutive days with an
absolute neutrophil count > .5  109/L (without granulocyte colonye-
stimulating factor support) and transfusion-independent platelets > 20 
109/L or higher for 7 consecutive days, respectively. Sustained donor engraft-
ment was deﬁned as sustained donor-derived count recovery with full donor
chimerism (>95% donor hematopoiesis). Full donor chimerism was deter-
mined by quantitative polymerase chain reaction of informative polymorphic
short tandem repeat (STR) regions of DNA from donor and recipient using
AmpFlSTR Identiﬁler PlusPCR Ampliﬁcation kit (Applied Biosystems, Carlsbad,
CA). Patients who survived >42 days after transplantation and who failed to
achieve myeloid engraftment were considered to have primary graft failure.
Secondary graft failure was deﬁned as the loss of the engraftment.
Assessment of graft-versus-host disease, nonrelapse mortality, relapse, and
overall survival
Recipients were evaluated weekly for development and grading of acute
graft-versus-host disease (GVHD). Acute and chronic GVHD were diagnosed
and graded according to the standard criteria [10-12]. Patients dying
Table 1
Patients, Cord Blood Grafts, and Transplantation Characteristics (N ¼ 157)
Characteristic Value
Age, median (range), yr 20 (1-60)
Body weight, median (range), kg 52 (3-110)
Gender, male 81 of 157 (52)
Underlying disease
AML 56 of 157 (36)
ALL 51 of 157 (32)
Immunodeﬁciencies 16 of 157 (10)
Metabolic diseases 4 of 157 (3)
Non-Hodgkin lymphoma 10 of 157 (6)
Hodgkin disease 10 of 157 (6)
CML 6 of 157 (4)
MDS 4 of 157 (3)
Conditioning regimen
Thiotepa/Flu/Bu/ATG* 96 of 157 (61)
TBI/Cy/VP16/ATG 39 of 157 (25)
Bu/Cy/ATG 11 of 157 (7)
TBI/Cy/ATG 3 of 157 (2)
Othery 8 of 157 (5)
GVHD prophylaxisz
CsA-PDN 80 of 155 (52)
CsA-MMF 55 of 155 (36)
Other 20 of 155 (12)
HLA-A, -B antigen, -DRB1 allele match to patient
6/6 33 of 155 (21)
5/6 63 of 155 (41)
4/6 59 of 155 (38)
ABO blood group mismatch
Major 37 of 147 (25)
Minor 34 of 147 (23)
None 76 of 147 (52)
Donor-recipient sex match
Male-male 37 of 141 (26)
Male-female 31 of 141 (22)
Female-male 40 of 141 (28)
Female-female 33 of 141 (24)
Donor-recipient CMV serology
Donor and recipient negative 39 of 157 (25)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; Flu, ﬂu-
darabine; Bu, busulfan; ATG, antithymocyte globulin; Cy, cyclophospha-
mide; TBI, total body irradiation; VP16, etoposide; CsA, cyclosporine; PDN,
prednisone; MMF, mycophenolate mophetil; CMV, cytomegalovirus.
Data presented are n (%) unless otherwise indicated.
* The most conditioning regimen used was thiotepa (10 mg/kg i.v), Flu
(150 mg/m2 i.v), Bu (9.6 mg/m2 i.v) and in vivo T cell depletion with
antithymocyte globulin (6 to 10 mg/kg i.v).
y This is a miscellaneous group including patients who received different
conditioning regimen as thiotepa/Flu/Cy/ATG, Bu/Cy/melphalan (Mel)/ATG,
ﬂudarabine, AraC (cytarabine), G-CSF (FLAG)/idarubicin (Ida)/melphalan
(Mel)/ATG, treosulfan/Cy, and Flu/Cy/TBI.
z GVHD prophylaxis included CsA (1.5 mg mg/kg/12 hours i.v followed by
3 to 5 mg/kg/12 hours orally when oral intake was possible and slow
tapering starting between day þ90 and þ180 if feasible. CsA was combined
with short-course of steroids (1 mg/kg/daily) from day þ14 to þ28 or MMF
(15 mg/kg/day from 1 to þ30 day).
Table 2
Cell Recoveries after Dilution and Wash Method
CB Unit
Characteristics
All CB Units FACT CBB
(n ¼ 100)
non-FACT
CBB
(n ¼ 57)
P
Value
TNC, median (range)  107/kg
Prethaw 3.8 (2.1-27) 4 (2-26) 3.9 (2-25) .883
Post-thaw 3.4 (2-26) 3.9 (1.9-26) 3 (1.8-20) .279
TNC recovery,
% (range)
84 (45-178) 88 (45-178) 83 (51-157) .075
CD34þ, median (range),  105/kg
Prethaw 1.9 (1.1-26) 2 (1.1-9) 1.9 (1-7) .805
Post-thaw 1.3 (1-23) 1 (0.4-23) 1 (0.4-10) .419
CD34þ recovery (%) 75 (35-163) 76 (35-163) 73 (35-146) .339
CFU, median (range),  104 kg
Prethaw 6 (10-37) 5 (10-37) 7 (5-35) .232
Post-thaw 3 (10-68) 3 (10-64) 3 (10-65) .155
CFU recovery (%) 61 (63-68) 67 (60-72) 44 (69-162) .378
CD34þ cell viability, median (range), %
Prefreezing 83 (36-100) 78 (36-100) 90 (52-100) .069
Post-thaw 89 (50-100) 89 (50-100) 93 (51-100) .132
Clonogenic efﬁciency, median (range), %
Pre-freezing 36 (45-99) 38 (8-92) 32 (4-99) .567
Post-thaw 24 (6-91) 27 (4-76) 21 (4-91) .006
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Nonrelapse mortality (NRM) was deﬁned as death from any cause without
evidence of relapse. Overall survival (OS) was deﬁned as survival from the
time of transplantation.
Statistical methods
Baseline characteristics were described as median and range for quan-
titative variables and frequency and percentages for categorical variables.
Comparisons of quantitative variables were done by Mann-Whitney test.
Binary logistic regression was used for univariate and multivariate analyses
to estimate the association of risk factors with cardiovascular AIE. Charac-
teristics selected for inclusion in the multivariate model were those with
some indication of association in univariate analysis (P < .10). Results were
expressed as odds ratios (OR) and their corresponding 95% conﬁdence in-
tervals [CI]. Survival probability was calculated using Kaplan-Meier esti-
mation [13]. Cumulative incidence curves were used in a competing risk
setting to calculate the cumulative incidence of neutrophil and platelet
engraftment, acute GVHD, cGVHD, relapse, and NRM [14]. Death withoutrelapse was the competing event for relapse. Relapse or death without
developing acute or chronic GVHDwas the competing event for acute GVHD
and cGVHD, respectively. Death without engraftment was the competing
event for neutrophil and platelet engraftment. All statistical tests were
conducted using the SPSS statistical software (SPSS version 15.0, Chicago, IL).
Cumulative incidence with competing risks was conducted in R software,
version 2.15.2 (The CRAN project).
RESULTS
Patients and CB Units Characteristics
The main characteristics of the 157 patients included in
the study are shown in Table 1. The median age at trans-
plantation was 20 years (range, 1 to 60) and median weight
52 kg (range, 3 to 110 kg). The units were 6/6 (n¼ 33, 21%), 5/
6 (n ¼ 63, 41%), and 4/6 (n ¼ 59, 38%) HLA matched to the
patient. One hundred and six patients (68%) underwent
transplantation for acute leukemia. Median follow-upwas 36
months (range, 7 to 96).
Of all CB units used in the study, 90 (58%) were obtained
from international and 67 (42%) from Spanish CBBs. Of the
Spanish CBBs, 52 (33%) CB units were cryopreserved and
stored in the Barcelona CBB. On the day of infusion, all CB
units were thawed and washed using automated method in
the Banc de Sang i Teixits cell therapy service and provided to
the respective transplantation center. One hundred (64%)
international CBBs were accredited by the Foundation for the
Accreditation of Cellular Therapy (FACT). In 109 (69%) CB
units, RBC reduction was performed. Thirty-seven (25%) pa-
tients received CB units with major ABO blood mismatch.
Characteristic of Cellular, Noncellular Components, and
Cellular Recoveries
Precryopreservation, post-thaw cell doses, viability, and
recoveries are summarized in Table 2. The median TNC cell
doses infusedwas 3.4107/kg (range, 2 to 26) with amedian
TNC recovery of 84% (range, 45% to 178%). Median of CD34þ
cell doses was 1.3  105/kg (range, 1 to 23). For CBU obtained
from FACT-accredited CBBs, median TNC, CD34þ, and CFU
were 88% (range, 45% to 178%), 76% (range, 35% to 163%), and
67% (range, 60% to 72%), respectively.
CB units had a median infusion volume of 100 mL (range,
31 to 188). After washing, median volume of residual infused
RBC was .05 mL/kg (range, .001 to .108). Median content of
Table 3
Cardiovascular and Noncardiovascular AIE by Maximum CTCAE v4 Criteria
Patients with infusion reactions, n (%)* 52 of 157 (33%)
Total of AIEy 118
Cardiovascular events (n ¼ 95)
Grade 1 (n ¼ 73)
Bradycardia 23 of 73 (32%)
Tachycardia 4 of 73 (5.5%)
Hypertension 28 of 73 (38%)
Hypotension 14 of 73 (19%)
Chest pain 4 of 73 (5.5%)
Grade 2 (n ¼ 22)
Bradycardia 3 of 22 (13.5%)
Tachycardia 5 of 22 (23%)
Hypertension 11 of 22 (50%)
Hypotension 3 of 22 (13.5%)
Noncardiovascular events (n ¼ 23)
Grade 1
Nausea and vomiting 15 of 23 (65%)
Lethargy 2 of 23 (9%)
Hemoglobinuria 6 of 23 (26%)
Grade 2
None -
* Percentages of AIE are referred to each grade of severity.
y In the entire cohort, there were patients who presented more than 1
AIE.
Table 4
Univariate and Multivariate Analysis of Risk Factors Associated with
Cardiovascular AIE according Patients and CB Grafts Characteristics
Characteristics OR (95% CI) P Value
Univariate analysis
Age, yr <.001
Adult* 24.5 (9.4-64.2)
Gender .338
Female* .7 (0.4-1.4)
Weight, kg .9 (.89-.94) <.001
Underlying disease
Malignant* 2.5 (1.2-5) .011
Previous treatments
<2 lines 2.2 (.6-8) .062
2 lines .5 (.1-2.7)
>2 lines*
Previous ASCT
Yes* 1.8 (.5-6.6) .398
Volume of infused CB products, mL 1 (.99-1.01) .733
Duration of infusion, min .9 (.89-.98) .002
Rate of infusion, mL/min 1.1 (.9-1.2) .091
Rate of infusion per kg, (mL/min)/kg 1.9 (1.8-2.2) <.001
Number of TNC infused,  107/kg 1.5 (1.3-1.7) <.001
Dose of DMSO, g/kg 2.4 (.7-8.2) .172
Dose of dextran, g/kg 3.2 (.6-17) .168
RBC, mL/kg 1.9 (1.5-2.4) <.001
RBC content
Replete 1.7 (.9-3.3) .083
Depleted*
ABO incompatibility
None 1.01 (.4-2.5) .938
Major 1.2 (.4-3.3)
Minor*
Accreditation
FACT* .9 (.4-1.8) .757
Multivariate analysis
Number of TNC infused,  107/kg 1.2 (1.1-1.4) .009
Weight, kg .93 (.9-.95) <.001
Rate per kg, (mL/min)/kg 1.5 (1.2-1.8) <.001
ASCT indicates autologous stem cell transplantation.
* Reference category.
N. Castillo et al. / Biol Blood Marrow Transplant 21 (2015) 682e687 685DMSO and dextran was .01 g/kg (range, .03 to .18) and .02
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Infusion Procedure and Adverse Reactions
ThemediantimetoinfuseCBunitswas22minutes(range,10
to 48). The incidence and severity of AIE graded by CTCAE v4.0
criteria are summarized in Table 3. One hundred and ﬁve pa-
tients (68%) had no AIE. The remaining 52 patients (33%) pre-
sented AIE, even though all were grades mild (1) to moderate
(2),accordingtoCTCAEv4.0criteria.Althoughwenoticedatotal
of118infusionreactions,remarkablywedidnotobserveanyAIE
with severity grade higher than 2. The most frequently AIE
detectedwere cardiovascular events (n¼ 95, 81%)presented in
50 patients (32%). Six patientswith grade 2 hypertensionwere
treatedwith furosemide i.v or antihypertensive per os. Grade 1
nausea/vomiting was treated by antiemetics i.v. All immediate
AIE occurred during the administration of CB unit and were
resolvedsoonafterreceivingtheappropriateabove-mentioned
treatment. The remaining patients who presented AIE did not
require intervention.
Factors associated with cardiovascular AIE
Factors associated with cardiovascular AIE occurrence in
univariate analysis were older age, lower weight, malignant
disease, more than 2 previous lines of treatment, times of
infusion (shorter duration, faster rate, and faster rate per
kilogram), higher infused TNC cell dose, and higher dose of
infused RBC and RBC-replete CB units. In multivariate anal-
ysis, higher dose of infused TNC, lowerweight, and faster rate
of infusion per kilogram remained as predictive for cardio-
vascular AIE occurrence (OR, 1.2; 95% CI, 1.1 to 1.4; P < .001;
OR, .94; 95% CI, .9 to .97; P < .001; and OR, 1.5; 95% CI, 1.2 to
1.8; P < .001, respectively) as shown in Table 4.
General Outcomes
Engraftment
Nineteen patients (12%) died before engraftment: 8 from
primary graft failure, 8 from septic shock, and 3 from mul-
tiorgan failure with unknown cause. Overall, 17 (11%) pa-
tients presented with graft failure. Among the 9 patients
alive after primary graft failure, 5 received a second umbilicalCB transplantation, 2 received haploidentical transplantation
as salvage treatment, and the remaining 2 patients had
autologous recovery.
The remaining 121 (77%) patients reached neutrophil
engraftment with a median of 26 days (95% CI, 24 to 28). The
cumulative incidences of neutrophil engraftment at 30 and
50 days were 62% (95% CI, 54 to 70) and 84% (95% CI, 83 to
93), respectively (Figure 1A). One hundred nineteen patients
who engrafted showed full donor chimerism at the time of
recovery. Five patients who presented engraftment by
day þ42 experienced secondary graft failure. One hundred
twenty-one patients had platelet engraftment by day þ42.
The cumulative incidences of platelet engraftment at 30 and
50 dayswere 20% (95% CI,14 to 26) and 69% (95% CI, 74 to 86),
respectively (Figure 1B).
GVHD
Grade II to IV acute GVHD occurred in 43 patients (grade II
in 24 patients, grade III in 10 patients, and grade IV in 9 pa-
tients) at a median time of 24 days (range, 14 to 97). The
cumulative incidence of grade II to IV acute GVHD at day 100
after CB transplantation was 29% (95% CI, 22 to 36). Twenty
(17%) of 115 evaluable patients developed cGVHD. cGVHD
was limited in 9 patients and extensive in 11 patients. The
median time to the development of cGVHD was 124 days
(range,117 to 2295). The 1- and 2-year cumulative incidences
of cGVHD were 11% (95% CI, 5 to 17) and 17% (95% CI, 10 to
24), respectively.
Figure 1. (A) Shows neutrophil recovery for the whole cohort. (B) Shows platelet recovery for the whole cohort.
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A total of 81 (52%) patients died of transplantation-
related causes. Infectious complication was the main cause
of death (n¼ 46, 29%) followed by GVHD in 16 (10%) patients
(14 for acute and 2 for chronic), graft failure in 8 (5%), mul-
tiorgan failure in 7 (4.5%) patients, and other causes in 4
(2.5%) patients. The cumulative incidence of NRM at 1, 2, and
3 years was 36% (95% CI, 28 to 44), 39% (95% CI, 31 to 47), and
42% (95% CI, 34 to 50), respectively.
Relapse and OS
Twenty-two (14%) patients relapsed at median time of 6
months (range, 1 to 75) and 9 (6%) died from this cause. The
1-, 2-, and 3-year cumulative incidences of relapse were 9%
(95% CI, 4 to 14), 12% (95% CI, 7 to 17), and 14% (95% CI, 8 to
20), respectively. The probabilities of OS at 1, 2 and 3 years
was 55% (95% CI, 44 to 60), 53% (95% CI, 45 to 61), 45% (95% CI,
37 to 53).
DISCUSSION
Our study shows that dilution and wash using the auto-
mated method to process CB units before infusion provides
high percentages of cell recoveries and engraftment with a
very low incidence of AIE and no serious toxicities.
The aim of the washing approach is to decrease AIE after
CB transplantation. Although the true incidence of AIE re-
mains unknown, prior studies report an incidence of AIE
between 60% and 80%, which is higher than the incidence we
found in our population (33% of patients). Moreover, we did
not have any grade 3 to 5 reactions and all AIE after CB
infusion were described as mild and transient. Additionally,
the most frequent AIE reported previously were cardiovas-
cular (hypertension) [15,16], as well as in our study.
AIE after CBT have been related to cryoprotectant agents,
dead cell debris, lysis of RBC, or ABO incompatibility between
donor and recipient. Serious AIE (especially cardiovascular)
have been attributed to components of the cryopreservation
solution, such as DMSO and/or dextran [17,18], as these could
promote an acute extreme volume expansion.
The occurrence of AIE has been directly attributed to
DMSO administration [17] in a dose-dependent manner and,
in an attempt to minimize AIE, many institutions have cho-
sen to limit the total amount of DMSO infused, whereas other
groups have adopted washing protocols [18,19]. In our study,
the median dose of DMSO after washing was very low,
minimizing the incidence of AIE.Recently, some reports have suggested that dextran is a
potential causative agent contributing to severe AIE [4,20-
22], such as myocardial ischemia or anaphylactic reactions.
Dextran could promote acute volume expansion and idio-
syncratic reactions, even at low concentrations. In our study,
the median infused dextran dose was lower than the previ-
ously described dose capable of triggering AIEs [23,24],
which could potentially explain why we did not detect any
severe or lethal reactions immediately or over the ﬁrst 24
hours after infusion.
Renal impairment after CB infusion has been previously
associated with free hemoglobin and cellular debris [25].
Chow et al. [26] evaluated AIE after RBC-replete infusions
and showed more hemoglobinuria in nonwashed infusions
than in washed infusions. Barker et al. [27] developed a
“nonwash” method to prepare units before double CB
transplantations, adopting the policy of infusing exclusively
RBC-depleted CB units, in an attempt tominimize AIE related
to RBC debris leading to acute renal failure [28,29]. Based on
our experience, we do not consider units containing RBC as a
limitation to selecting CB units for infusion, as we apply the
dilution and “wash” method, decreasing hemolyzed RBC,
free hemoglobin, and membrane fragments. Of note, we did
not ﬁnd renal impairment in our patients, but we did observe
the use of RBC-replete CB units as risk factor for cardiovas-
cular AIE, with a trend to statistical signiﬁcance. Highlighting
the occurrence of serious or life-threatening reactions asso-
ciated with CB infusions, the National Marrow Donor Pro-
gram and the Food and Drug Administration recently
provided recommendations for thawing and washing RBC-
replete CB units [5]. On the other hand, premedication
administered before infusion may help to reduce AIE.
As risk factors associated with AIE occurrence, we
conﬁrmed higher TNC cell dose infused, lower recipient’s
weight, and rate of infusion per kilogram, suggesting special
consideration in small pediatric patients. Nonetheless, our
study presents limitations, such as the retrospective nature
of the analysis, the wide diversity of population regarding
the age (and inherently the weight of patients), and under-
lying diseases affecting the recipients.
Preparation of CB units by albumin-dextran dilution and
centrifugation (wash) before infusion has been challenged
because of its risk of cell loss. This study demonstrates that
the dilution and wash method allows minimization of the
amount of DMSO that could affect the function of
HPC, inﬂuencing short- and long-term engraftment. We
N. Castillo et al. / Biol Blood Marrow Transplant 21 (2015) 682e687 687conﬁrmed a high rate of sustained donor neutrophil and
platelet engraftment, which supports that this automated
method maintains cell viability and functionality, reducing
the risk of cell loss, and our results are in line with those of
other groups using dilution without centrifugation. Addi-
tionally, in accordance with other authors, we observed
higher rate of recoveries in CB units provided by FACT-
accredited banks, showing differences in CB banking prac-
tices [30].
In conclusion, our study demonstrates that dilution and
wash with this automated method is a feasible option in CB
transplantation, with a safe proﬁle regarding AIE, that yields
good recovery of cells and provides a high rate of engraft-
ment in patients who receive unrelated single CB units for
transplantation. The availability of this automated method
for graft dilution and wash would facilitate the widespread
use of this approach for CB administration, improving safety
and, probably, outcomes.
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